Effects of The Effects of Dietary Oils on Fasting Lipoprotein Lipids

A Randomized Double Blind Controlled Crossover Trial to Assess the Effects of Dietary Oils on Fasting Lipoprotein Lipids

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01925716

Enrollment

Registered

2013-08-20

Start date

2013-03-31

Completion date

2013-08-31

Last updated

2013-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

cholesterol,LDL, vegetable oils, heart diseases

Brief summary

The objectives of this clinical trial are to assess the effects of dietary oils on blood lipids and other aspects of the fasting lipoprotein profile in healthy men and women with elevated cholesterol

Interventions

OTHERCorn oil

corn oil 56 g/day for 21 days

OTHEROlive oil

olive oil 56 g /day for 21 days

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 74 Years

Healthy volunteers

Yes

Inclusion criteria

* Fasting LDL-C level equal to or greater than 130 mg/dL and less than 200 mg/dL at visit 1 * Fasting triglycerides less than or equal to 350 mg/dL at visit 1

Exclusion criteria

* Has coronary heart disease or coronary heart disease risk risk equivalent, such as diabetes, atherosclerosis, etc * Taking lipid medications intended to alter the lipids profile, including but not limited to statins, bile acid sequestrants, etc. * Uncontrolled hypertension (systolic greater than or equal to 160 mm Hg or diastolic greater than or equal to 100 mm Hg)

Design outcomes

Primary

Measure	Time frame
Low Density Lipoprotein cholesterol	Time Frame: baseline (average days -7 and 0) and the end of each treatment period [Treatment 1 averages of days 19 and 21and Treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks

Secondary

Measure	Time frame
total cholesterol	baseline (average of days -7 and 0) and the end of each treatment period [Treatment I average of days 19 and 21) and treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks

Other

Measure	Time frame
High density lipoprotein cholesterol	baseline (average of days -7 and 0) and the end of each treatment period [Treatment I average of days 19 and 21) and treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks
Non-HDL-Cholesterol	baseline (average of days -7 and 0) and the end of each treatment period [Treatment I average of days 19 and 21) and Treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks
Triglycerides	baseline (average of days -7 and 0) and the end of each treatment period [Treatment I average of days 19 and 21) and Treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks
Total cholesterol/HDL-C ratio	baseline (average of days -7 and 0) and the end of each treatment period [Treatment I average of days 19 and 21) and Treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026